Experimental HER2 drug trial halted early – what it means
NCT ID NCT05013554
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested an experimental drug called SAR443216 in 44 adults with advanced HER2-expressing solid tumors (such as breast, lung, or gastric cancer) that had come back or stopped responding to standard treatments. The study aimed to find a safe dose and check for early signs of tumor shrinkage. However, the trial was terminated, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SAR443216 (an experimental drug given by IV or injection)
What this could lead to
If successful, this could point toward a new treatment option for people with HER2-expressing solid tumors that have stopped responding to other therapies.
What could go wrong
This was a very early (Phase 1) trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 0560002
Ghent, 9000, Belgium
-
Investigational Site Number : 1580001
Taichung, 404, Taiwan
-
Investigational Site Number : 1580002
Tainan, 704, Taiwan
-
Investigational Site Number : 2500001
Pierre-Bénite, 69495, France
-
Investigational Site Number : 2500002
Villejuif, 94800, France
-
Investigational Site Number : 4100001
Seoul, Seoul-teukbyeolsi, 03080, South Korea
-
Investigational Site Number : 4100002
Seoul, Seoul-teukbyeolsi, 05505, South Korea
-
Investigational Site Number : 7240001
Madrid, Madrid, Comunidad de, 28040, Spain
-
Investigational Site Number : 7240002
Madrid / Madrid, Madrid, Comunidad de, 28050, Spain
-
Investigational Site Number : 7240003
Barcelona, Barcelona [Barcelona], 08035, Spain
-
~University of Texas - MD Anderson Cancer Center Site Number : 8400002
Houston, Texas, 77030, United States